Skip to main content

Korenberg Matthew E's Form 4 filing

Ligand Pharmaceuticals Inc (LGND) · filed Aug 26, 2024

Accession no.
0002001011-24-000078
Filed
Aug 26, 2024
Trade date
Aug 22-26, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions. Open-market sales total $1.99M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Korenberg Matthew ECIK 0001649903Officer (President & COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 22, 2024Common StockSSaleDisposed−1,157$105.54F1−$122,109.7867,211Direct
Aug 23, 2024Common StockSSaleDisposed−2,037$104.09F2−$212,031.3365,174Direct
Aug 23, 2024Common StockSSaleDisposed−4,275$105.13F3−$449,430.7560,899Direct
Aug 26, 2024Common StockSSaleDisposed−6,177$105.02F4−$648,708.5454,722Direct
Aug 26, 2024Common StockSSaleDisposed−5,212$106.32F5−$554,139.8449,510Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.2500 to $105.6500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.0000 to $105.4450. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.7200 to $105.6700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.8100 to $106.6900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)